BioMarin Pharma (BMRN): Executing Well But For How Long - Piper Jaffray

August 18, 2016 8:46 AM EDT
Get Alerts BMRN Hot Sheet
Price: $85.21 -1.97%

Rating Summary:
    20 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade BMRN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as the company continues to execute and transition to (non-GAAP) profitability. The analyst believes BMRN is well positioned for NT growth as Kuvan and Vimizim continue to grow, along with Batten's positioned to launch next year.

Valuation, on the other hand, seems lofty, as there is still risk in key pipeline programs (hemophilia A gene therapy, vosoritide for achondroplasia, and pegvaliase PKU) that may be underappreciated.

The base business continues to perform well and the Batten's program appears well positioned to add another layer of growth. We do note many of the company's programs still retain some level of theoretical risk, including hemophilia A (thrombosis/regulatory, competitive dynamics), vosoritide (strength of effect with no placebo), pegvaliase (immune complexes) which appear underappreciated by investors. That said, consensus estimates do not have substantial contribution from these products and probably underestimate margin expansion opportunities.

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $93.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Joshua Schimmer

Add Your Comment